Bright Minds Biosciences Inc. Common Stock (DRUG) is a publicly traded Healthcare sector company. As of May 21, 2026, DRUG trades at $83.00 with a market cap of $734.04M and a P/E ratio of 0.00. DRUG moved +11.07% today. Year to date, DRUG is +3.46%; over the trailing twelve months it is +155.02%. Its 52-week range spans $0.94 to $123.75. Analyst consensus is strong buy with an average price target of $145.67. Rallies surfaces DRUG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Recent DRUG insider activity includes Cormorant Asset Management, LP sold 109.33K, Cormorant Asset Management, LP bought 184.33K, Cormorant Asset Management, LP bought 39.74K, Cormorant Asset Management, LP bought 7.15K, and Cormorant Asset Management, LP bought 3.11K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
| Metric | Value |
|---|---|
| Price | $83.00 |
| Market Cap | $734.04M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $123.75 |
| 52-Week Low | $0.94 |
| Volume | 41 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover DRUG: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $145.67.